Kahn Brothers Group Inc. Has $50.63 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Kahn Brothers Group Inc. lessened its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 12.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 508,908 shares of the company's stock after selling 71,580 shares during the period. Merck & Co., Inc. comprises 10.9% of Kahn Brothers Group Inc.'s holdings, making the stock its 2nd largest holding. Kahn Brothers Group Inc.'s holdings in Merck & Co., Inc. were worth $50,627,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Merck & Co., Inc. by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 251,096,107 shares of the company's stock valued at $24,979,041,000 after buying an additional 1,292,192 shares in the last quarter. Wellington Management Group LLP increased its stake in Merck & Co., Inc. by 6.5% in the fourth quarter. Wellington Management Group LLP now owns 80,742,030 shares of the company's stock valued at $8,032,217,000 after acquiring an additional 4,932,647 shares during the last quarter. Geode Capital Management LLC raised its position in Merck & Co., Inc. by 3.4% during the fourth quarter. Geode Capital Management LLC now owns 61,181,863 shares of the company's stock valued at $6,072,582,000 after purchasing an additional 2,026,859 shares in the last quarter. Norges Bank bought a new stake in Merck & Co., Inc. during the fourth quarter worth $3,479,799,000. Finally, Northern Trust Corp boosted its holdings in shares of Merck & Co., Inc. by 16.8% in the 4th quarter. Northern Trust Corp now owns 31,377,107 shares of the company's stock valued at $3,121,395,000 after purchasing an additional 4,511,742 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on MRK. BMO Capital Markets lowered their price target on Merck & Co., Inc. from $105.00 to $96.00 and set a "market perform" rating for the company in a report on Wednesday, February 5th. Guggenheim reissued a "buy" rating and issued a $115.00 target price on shares of Merck & Co., Inc. in a report on Thursday, April 17th. Bank of America reduced their price target on shares of Merck & Co., Inc. from $118.00 to $112.00 and set a "buy" rating on the stock in a research note on Wednesday, February 5th. Leerink Partners lowered their price objective on shares of Merck & Co., Inc. from $136.00 to $119.00 and set an "outperform" rating for the company in a research report on Monday, January 13th. Finally, Morgan Stanley cut their target price on shares of Merck & Co., Inc. from $113.00 to $106.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. Twelve equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of "Moderate Buy" and an average price target of $111.13.

Merck & Co., Inc. Trading Down 2.3 %

NYSE:MRK opened at $75.88 on Friday. Merck & Co., Inc. has a 52 week low of $75.82 and a 52 week high of $134.63. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36. The firm's fifty day moving average is $85.27 and its 200-day moving average is $93.22. The firm has a market cap of $190.54 billion, a P/E ratio of 11.27, a P/E/G ratio of 0.77 and a beta of 0.43.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The company reported $2.22 EPS for the quarter, beating analysts' consensus estimates of $2.16 by $0.06. Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. The business had revenue of $15.53 billion for the quarter, compared to analysts' expectations of $15.59 billion. During the same quarter in the prior year, the firm posted $2.07 earnings per share. The business's quarterly revenue was down 1.6% compared to the same quarter last year. Equities analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. declared that its Board of Directors has authorized a stock repurchase plan on Tuesday, January 28th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 4.1% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's management believes its shares are undervalued.

Insider Buying and Selling

In related news, SVP Dalton E. Smart III sold 4,262 shares of the stock in a transaction on Friday, April 25th. The shares were sold at an average price of $82.76, for a total transaction of $352,723.12. Following the transaction, the senior vice president now directly owns 7,778 shares of the company's stock, valued at $643,707.28. This represents a 35.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.13% of the stock is currently owned by insiders.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.